Read by QxMD icon Read

Plasma cell myeloma

Jasmita Dass, Sudheer Arava, Pravas Chandra Mishra, Amit Kumar Dinda, Hara Prasad Pati
Introduction: Plasma cells (PCs) have conventionally been counted on the bone marrow aspirate, and small focal involvement may be missed even on bone marrow biopsy sections. Material and Methods: We aimed to study the role of CD138, CD56, anti-κ, and anti-λ immunohistochemistry (IHC) to separate PC myeloma from reactive plasmacytosis and to study the utility of these in cases suspected as myelomas and lacking >10% PCs on bone marrow aspirate. The study comprised 35 diagnosed myelomas, 20 reactive plasmacytosis, and 19 M-band positive suspected myelomas...
January 2019: South Asian Journal of Cancer
Jian Xu, Yan Su, Aoshuang Xu, Fengjuan Fan, Shidai Mu, Lei Chen, Zhangbo Chu, Bo Zhang, Haifan Huang, Jiasi Zhang, Jun Deng, Lisha Ai, Chunyan Sun, Yu Hu
Inherent or acquired resistance to chemotherapeutic drugs is still an obstacle for the treatment of multiple myeloma (MM). MicroRNA dysregulation is related to the development of chemoresistance in cancers. However, its role in chemoresistance of MM is largely unknown. Here we demonstrated that miR-221/222 were upregulated in plasma cells from patients with MM, especially those with relapsed or refractory disease. Moreover, expression levels of miR-221/222 were inversely correlated with dexamethasone (Dex) sensitivity of human MM cell lines...
January 24, 2019: Molecular Therapy: the Journal of the American Society of Gene Therapy
M Zapletalova, D Krejci, J Jarkovský, J Muzik, L L Pour Dusek
BACKGROUND: Plasma cell leukemia (PCL) is a rare but most aggressive form of monoclonal gammopathies. PCL is characterized by the presence of clonal plasma cells in peripheral blood. There are two forms of PCL - primary which presents de novo in patients with no evidence of previous multiple myeloma and secondary which is a leukemic transformation of relapsed or refractory dis-ease in patients with previously recognized multiple myeloma. MATERIALS AND METHODS: This is the first study to provide information on PCL epidemiology in the Czech population us-ing The Czech National Cancer Registry (CNCR) as the basic source of data for the population-based evaluation of PCL epidemiology...
2019: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
M Žárska, D Vrábel, R Bezdekova, M Štork, M Jarošová, Z Adam, M Krejčí, L Pour, S Ševčíková
BACKGROUND: Plasma cell leukemia (PCL) is a rare dis-ease and possibly the most aggressive form of monoclonal gammopathy. It is classified into two forms -  primary PCL that occurs without a previously identifiable multiple myeloma stage, and secondary PCL that develops from previously dia-gnosed multiple myeloma. These two forms have different cytogenetic and molecular profiles, but both forms have an aggressive clinical course. Combinations of different therapeutic approaches includ-ing autologous stem cell transplantation and currently proteasome inhibitors and immunomodulatory drugs are used to treat PCL...
2019: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
Suresh Manapuram, Hamza Hashmi
Multiple myeloma (MM) is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. With median age of 66 at the time of presentation, multiple myeloma is predominantly a disease of the elderly. The availability of new combination regimens and the enhanced safety of autologous hematopoietic stem cell transplant has increased the treatment options for elderly patients with multiple myeloma. We provide a summary of data supporting the current management of elderly patients with newly diagnosed multiple myeloma...
December 1, 2018: Curēus
Charlotte Pawlyn, Graham H Jackson
Myeloma outcomes have improved dramatically over the last decade as a result of novel therapies, several of which are now commonly continued to disease relapse. Physicians who do not work in haematology are therefore more likely than ever before to be consulted by a patient with myeloma, either for an unrelated condition or with a side effect of myeloma or its treatment. Myeloma is also the cancer most likely to be diagnosed in accident and emergency departments or by the acute physician and so an awareness of its presentation and management is especially important in these settings to enable early diagnosis and limit the morbidity associated with end organ damage...
February 2, 2019: British Journal of Hospital Medicine
Julia C Walk, Bruce P Ayati, Sarah A Holstein
Multiple myeloma (MM), a plasma cell cancer, is associated with many health challenges, including damage to the kidney by tubulointerstitial fibrosis. We develop a mathematical model which captures the qualitative behavior of the cell and protein populations involved. Specifically, we model the interaction between cells in the proximal tubule of the kidney, free light chains, renal fibroblasts, and myeloma cells. We analyze the model for steady-state solutions to find a mathematically and biologically relevant stable steady-state solution...
February 11, 2019: Scientific Reports
Amjd Ibraheem, Oshrat Attar-Schneider, Mahmoud Dabbah, Osnat Dolberg Jarchowsky, Shelly Tartakover Matalon, Michael Lishner, Liat Drucker
Multiple myeloma (MM) malignant plasma cells accumulate in the bone marrow (BM) where their interaction with the microenvironment promotes disease progression and drug resistance. Previously, we have shown that MM cells cocultured with BM-mesenchymal stem cells (MSCs) comodulated cells' phenotype in a MAPKs/translation initiation (TI)-dependent manner. Dissection of the coculture model showed that BM-MSCs secretomes and microvesicles (MVs) participate in this crosstalk. Here, we addressed the role of the BM-MSCs extracellular matrix (ECM)...
January 23, 2019: Translational Research: the Journal of Laboratory and Clinical Medicine
Ahmet Gulmez
Breast cancer is the most common cancer in women. In addition, it is the second leading cause of death after lung cancer.1 , 2 The prevalence of epidemiological studies in previous studies is 22%-26%. The risk of mortality due to breast cancer is around 18%.3 , 4 Multiple myeloma (MM) is a malignant disease of differentiated plasma cells. It is also the most common hematological neoplasm after lymphoma. Thirty five percent of MM patients are under the age of 65, 28% are between 65 and 74 of age and 37% are over the age of 75...
February 1, 2019: Current Problems in Cancer
F Andrea Rodríguez-Lagos, José V Sorlí, Michelle C Calviño-Naveira, Nuria Estañ Capell
Multiple Myeloma is a myeloproliferative disorder of plasma cells, which may be complicated with secondary amyloidosis. We report a 48 year old woman consulting to primary care for weight loss and malaise. An initial laboratory study revealed a hypogammaglobulinemia with a monoclonal component and lambda light chains. These results motivated her derivation to hematology: her serum calcium was 11.8 mg/dl, immunofluorescence showed a monoclonal component of lambda chains and urine Bence-Jones protein was positive...
November 2018: Revista Médica de Chile
Shinya Kawamoto, Yuji Hidaka, Yu Kaneko, Hideo Misawa, Katsuhiro Nagahori, Atsunori Yoshino, Takamitsu Okamura, Shinichi Ban, Yoshihiko Ueda, Tetsuro Takeda
Light chain proximal tubulopathy is a rare manifestation of monoclonal gammopathy. A 73-year-old Japanese woman was noted to have urinary protein and hypertension on health examination and visited the regional clinic. She was noted to have IgG λ M protein and suspected of multiple myeloma. She was referred to us with massive proteinuria (7.5 g/g creatinine) and Bence Jones proteinuria without renal dysfunction. A renal biopsy revealed no glomerular abnormalities, but a tubular cast was observed partially in tubules without tubular atrophy or a crystalline structure...
February 5, 2019: CEN Case Reports
Hanqing Li, Feng Li, Xiaogang Zhou, Jiangang Mei, Ping Song, Zhiming An, Qian Zhao, Xing Guo, Xuli Wang, Yongping Zhai
The aim of our study was to evaluate the prognostic impact of minimal residual disease (MRD) and high-risk cytogenetics (HRCs) on outcomes in multiple myeloma (MM) patients. We applied multiparameter flow cytometry (MFC) to detect MRD in 123 consecutive patients diagnosed with MM for the first time who achieved very good partial remission (VGPR) or better after bortezomib or thalidomide-based induction therapy. Moreover, we examined the cytogenetic features of MM patients using magnetic-activated cell sorting and interphase fluorescence in situ hybridization (MACS-iFISH) at diagnosis...
February 5, 2019: Annals of Hematology
Roland Christian Schelker, Matthias Grube, Albrecht Reichle, Beate Wagner, Wolfgang Herr, Matthias Evert, Martin Vogelhuber
No abstract text is available yet for this article.
February 5, 2019: Leukemia & Lymphoma
Bingjie Li, Chenxi Liu, Guixue Cheng, Mengle Peng, Xiaosong Qin, Yong Liu, Yongzhe Li, Dongchun Qin
Multiple myeloma (MM) is an extremely complex plasma cell malignancy that is genetically heterogeneous. A recent Genome-wide association study (GWAS) indicated that variation at 2q22 (rs61070260) influences MM risk. This association has not been validated to date in a Chinese Han population. In this study, we evaluated the association between rs61070260 in LRP1B and MM risk in a Chinese Han population involving 739 MM patients and 592 healthy controls. Our results indicated that rs61070260 in LRP1B was significantly associated with MM susceptibility (P=3...
2019: Journal of Cancer
A Keith Stewart, Amrita Y Krishnan, Seema Singhal, Ralph V Boccia, Manish R Patel, Ruben Niesvizky, Asher A Chanan-Khan, Sikander Ailawadhi, Jochen Brumm, Kirsten E Mundt, Kyu Hong, Jacqueline McBride, Quyen Shon-Nguyen, Yuanyuan Xiao, Vanitha Ramakrishnan, Andrew G Polson, Divya Samineni, Douglas Leipold, Eric W Humke, James Scott McClellan, Jesus G Berdeja
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. This phase I study assessed safety, tolerability, maximum tolerated dose (MTD), anti-tumor activity, and pharmacokinetics of DFRF4539A in patients with relapsed/refractory multiple myeloma. DFRF4539A was administered at 0.3-2.4 mg/kg every 3 weeks or 0.8-1.1 mg/kg weekly as a single-agent by intravenous infusion to 39 patients...
February 4, 2019: Blood Cancer Journal
Dickran Kazandjian, Elizabeth Hill, Malin Hultcrantz, Evan H Rustad, Venkata Yellapantula, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alex Dew, Elli Papaemmanuil, Irina Maric, Mary Kwok, Ola Landgren
Caucasian Americans (CA) compared with African Americans (AA) have a twofold increased incidence of multiple myeloma (MM) and have an earlier age of diagnosis. However, there is sparse information regarding underlying biological differences across racial/ethnic groups. We characterized genetic alterations using a targeted next-generation sequencing assay called myTYPE, developed at MSKCC, allowing capture of somatic mutations, IgH translocations, gains/losses, and hyperdiploidy. Samples were obtained from the NIH Plasma Cell Dyscrasia Racial Disparity Cohort...
February 4, 2019: Blood Cancer Journal
Ruth Eichner, Vanesa Fernández-Sáiz, Bianca-Sabrina Targosz, Florian Bassermann
Multiple myeloma (MM) is the second most common hematological malignancy and results from the clonal amplification of plasma cells. Despite recent advances in treatment, MM remains incurable with a median survival time of only 5-6years, thus necessitating further insights into MM biology and exploitation of novel therapeutic approaches. Both the ubiquitin proteasome system (UPS) and the PI3K/Akt/mTOR signaling pathways have been implicated in the pathogenesis, and treatment of MM and different lines of evidence suggest a close cross talk between these central cell-regulatory signaling networks...
2019: International Review of Cell and Molecular Biology
Rodrigo Carlini Fernando, Diego Robles Mazzotti, Hatylas Azevedo, Alex Freire Sandes, Edgar Gil Rizzatti, Mariana Bleker de Oliveira, Veruska Lia Fook Alves, Angela Isabel Pereira Eugênio, Fabrício de Carvalho, Maria Aparecida Dalboni, David Correa Martins, Gisele Wally Braga Colleoni
A growing body of evidence suggests a key role of tumor microenvironment, especially for bone marrow mesenchymal stem cells (MSC), in the maintenance and progression of multiple myeloma (MM), through direct and indirect interactions with tumor plasma cells. Thus, this study aimed to investigate the gene expression and functional alterations of MSC from MM patients (MM-MSC) in comparison with their normal counterparts from normal donors (ND-MSC). Gene expression analysis (Affymetrix) was performed in MM-MSC and ND-MSC after in vitro expansion...
January 31, 2019: Scientific Reports
Uday Yanamandra, Prateek Deo, Kamal Kant Sahu, Ram Vasudevan Nampoothiri, Nalini Gupta, Anusree Prabhakaran, Deb Prasad Dhibhar, Alka Khadwal, Gaurav Prakash, Man Upadesh Singh Sachdeva, Deepesh Lad, Neelam Varma, Subhash Varma, Pankaj Malhotra
BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting. PATIENTS AND METHODS: In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE...
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
Markus B Heckmann, Shirin Doroudgar, Hugo A Katus, Lorenz H Lehmann
Multiple myeloma is a malignant disease, caused by an uncontrolled clonal proliferation of a specific group of white blood cells, the plasma cells. Clinical manifestations include bone pain due to osteolysis, hypercalcemia, anemia, and renal insufficiency. Proteasome inhibitors have substantially improved survival of patients suffering from multiple myeloma, providing an efficient treatment option mainly for relapsed and refractory multiple myeloma. Although constituting one substance class, bortezomib, carfilzomib, and ixazomib differ greatly regarding their non-hematologic side effects...
December 2018: Journal of Thoracic Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"